Onsite manufacture can accelerate your Phase I small molecule program

Dinesh Mistry

Dinesh has over 27 years of industry experience with over 26 years in EU/US regulatory strategy and submissions in in all phases of development (phases I-IV) in a variety of indications including orphan.

Diane Ostang

Diane Ostang, Delivery Director, has a background in Biomedical Engineering and brings over 22 years of industry experience across various therapeutic areas, with over 18 years as part of Fortrea team.

Richard Gambie

Richard has more than 27 years of industry experience from Pre-Clinical work in the Pharmaceutical sector to Data Management, CRA & Project Management, in multiple therapeutic areas, focusing on Ophthalmology over the last 8 years, joining For

Five breakthrough moments from AAIC 2025 that are reshaping Alzheimer's research

Non-invasive biomarkers: Promising future to reduce patients’ burden and accelerate drug development in MASH

Can innovation in clinical trial delivery meet the demands of increasing complexity in drug development?

Discover how innovation in complex clinical trial design can address growing clinical trial complexity and improve productivity in drug development.

Regulatory intelligence in action: Transforming compliance into strategy